Arcus Biosciences Inc (RCUS)
Return on equity (ROE)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | -283,000 | -307,000 | -267,000 | 53,000 | -123,000 |
| Total stockholders’ equity | US$ in thousands | 485,000 | 462,000 | 657,000 | 842,000 | 502,000 |
| ROE | -58.35% | -66.45% | -40.64% | 6.29% | -24.50% |
December 31, 2024 calculation
ROE = Net income ÷ Total stockholders’ equity
= $-283,000K ÷ $485,000K
= -58.35%
Based on the data provided, Arcus Biosciences Inc's Return on Equity (ROE) has shown significant fluctuations over the past five years.
Starting with a negative ROE of -24.50% in December 2020, the company managed to improve its performance in the following year with an ROE of 6.29% by December 2021. However, the trend reversed sharply in the subsequent years, with ROE declining to -40.64% by December 2022, and worsening further to -66.45% by December 2023.
By December 2024, Arcus Biosciences Inc's ROE stood at -58.35%, indicating ongoing challenges in generating profits relative to the shareholders' equity.
These fluctuations suggest that the company may be struggling with managing its assets efficiently to generate returns for its shareholders. It is essential for Arcus Biosciences Inc to focus on improving its operational efficiency and profitability to enhance its ROE in the future.
Peer comparison
Dec 31, 2024